ABIVAX Société Anonyme
ABVX
$5.94
$0.020.34%
Weiss Ratings | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -- | |||
Price History | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -24.33% | |||
30-Day Total Return | 0.68% | |||
60-Day Total Return | -16.46% | |||
90-Day Total Return | -42.44% | |||
Year to Date Total Return | -18.52% | |||
1-Year Total Return | -54.52% | |||
2-Year Total Return | -- | |||
3-Year Total Return | -- | |||
5-Year Total Return | -- | |||
52-Week High % Change | -65.22% | |||
52-Week Low % Change | 7.73% | |||
Price | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $17.02 | |||
52-Week Low Price | $5.50 | |||
52-Week Low Price (Date) | Jan 29, 2025 | |||
52-Week High Price (Date) | Mar 20, 2024 | |||
Valuation | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 372.90M | |||
Enterprise Value | 253.95M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -3.47 | |||
Earnings Per Share Growth | 0.88% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 38.14 | |||
Price/Book (Q) | 2.75 | |||
Enterprise Value/Revenue (TTM) | 26.00 | |||
Price | $5.94 | |||
Enterprise Value/EBITDA (TTM) | -1.38 | |||
Enterprise Value/EBIT | -1.38 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 62.92M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 33 1 53 83 09 63 | |||
Address | -- | |||
Website | www.abivax.com | |||
Country | France | |||
Year Founded | 2013 | |||
Profitability | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,885.05% | |||
Profit Margin | -1,965.41% | |||
Management Effectiveness | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -46.81% | |||
Return on Equity | -- | |||
Income Statement | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | 9.77M | |||
Revenue Per Share | $0.16 | |||
Gross Profit (TTM) | 9.77M | |||
EBITDA (TTM) | -183.76M | |||
EBIT (TTM) | -184.09M | |||
Net Income (TTM) | -191.94M | |||
Net Income Avl. to Common (TTM) | -191.94M | |||
Total Revenue Growth (Q YOY) | 198.49% | |||
Earnings Growth (Q YOY) | -55.38% | |||
EPS Diluted (TTM) | -3.47 | |||
EPS Diluted Growth (Q YOY) | 11.33% | |||
Balance Sheet | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 238.21M | |||
Cash Per Share (Q) | $3.79 | |||
Total Current Assets (Q) | 260.35M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 135.51M | |||
Current Ratio (Q) | 3.039 | |||
Book Value Per Share (Q) | $2.15 | |||
Total Assets (Q) | 304.82M | |||
Total Current Liabilities (Q) | 85.68M | |||
Total Debt (Q) | 121.46M | |||
Total Liabilities (Q) | 169.32M | |||
Total Common Equity (Q) | 135.51M | |||
Cash Flow | ABVX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 7.64M | |||
Cash from Financing (TTM) | 280.16M | |||
Net Change in Cash (TTM) | 116.89M | |||
Levered Free Cash Flow (TTM) | -96.55M | |||
Cash from Operations (TTM) | -167.34M | |||